• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpenoids
• Triterpenoids

Recent Advances in the Study of 7-Oxostigmasteryl Acetate (CAS: 33028-07-8): A Comprehensive Research Brief

7-Oxostigmasteryl Acetate (CAS: 33028-07-8) is a steroidal derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. Recent studies have explored its pharmacological properties, including its anti-inflammatory, anti-cancer, and immunomodulatory effects. This research brief aims to synthesize the latest findings on this compound, providing a comprehensive overview of its mechanisms of action, therapeutic potential, and current challenges in its development.

One of the most notable advancements in the study of 7-Oxostigmasteryl Acetate is its role in modulating inflammatory pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound significantly inhibits the production of pro-inflammatory cytokines such as TNF-α and IL-6 in macrophage cells. The study utilized molecular docking simulations to identify the compound's interaction with key inflammatory mediators, suggesting its potential as a novel anti-inflammatory agent. These findings are particularly relevant for the treatment of chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

In addition to its anti-inflammatory properties, 7-Oxostigmasteryl Acetate has shown promise in oncology research. A recent preclinical study highlighted its ability to induce apoptosis in various cancer cell lines, including breast and prostate cancer. The compound's mechanism of action involves the activation of the intrinsic apoptotic pathway, as evidenced by increased caspase-3 activity and mitochondrial membrane depolarization. Furthermore, synergistic effects were observed when 7-Oxostigmasteryl Acetate was combined with conventional chemotherapeutic agents, suggesting its potential as an adjunct therapy in cancer treatment regimens.

Despite these promising findings, several challenges remain in the development of 7-Oxostigmasteryl Acetate as a therapeutic agent. Issues such as poor bioavailability and limited solubility have been identified as major hurdles. Recent efforts have focused on the development of novel drug delivery systems, including liposomal formulations and nanoparticle-based carriers, to enhance the compound's pharmacokinetic profile. A 2024 study published in Pharmaceutical Research reported significant improvements in the oral bioavailability of 7-Oxostigmasteryl Acetate through the use of nanostructured lipid carriers, marking a critical step forward in its clinical translation.

In conclusion, 7-Oxostigmasteryl Acetate (CAS: 33028-07-8) represents a promising candidate for the treatment of inflammatory and oncological conditions. While significant progress has been made in understanding its pharmacological properties, further research is needed to address its formulation challenges and validate its efficacy in clinical settings. The ongoing development of advanced drug delivery systems offers a viable pathway to overcome these limitations, paving the way for future therapeutic applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)